Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis.
Provenzano L, Lobefaro R, Ligorio F, Zattarin E, Zambelli L, Sposetti C, Presti D, Montelatici G, Ficchì A, Martinetti A, Arata A, Del Vecchio M, Lauria Pantano C, Formisano B, Bianchi GV, Capri G, de Braud F, Vernieri C, Fucà G. Provenzano L, et al. Among authors: bianchi gv. Ther Adv Med Oncol. 2023 Apr 13;15:17588359231165978. doi: 10.1177/17588359231165978. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37063779 Free PMC article.
Is tumour sequencing effective for the identification of germline BRCA1/2 pathogenic variant carriers?
Azzollini J, Capone I, Duca M, Vingiani A, Piccolo A, Agnelli L, Tamborini E, Perrone F, Peissel B, Lorenzini D, Damian S, Vernieri C, Bianchi GV, Mantiero M, Ducceschi M, Polignano M, Niger M, Nichetti F, Proto C, Brambilla M, Colombo E, Stellato M, Conca E, Busico A, Manoukian S. Azzollini J, et al. Among authors: bianchi gv. Tumori. 2024 Sep 23:3008916241280127. doi: 10.1177/03008916241280127. Online ahead of print. Tumori. 2024. PMID: 39311051
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP).
Turner N, Saura C, Aftimos P, van den Tweel E, Oesterholt M, Koper N, Colleoni M, Kaczmarek E, Punie K, Song X, Armstrong A, Bianchi G, Stradella A, Ladoire S, Lim JSJ, Quenel-Tueux N, Tan TJ, Escrivá-de-Romaní S, O'Shaughnessy J; TULIP Trial Investigators. Turner N, et al. J Clin Oncol. 2024 Oct 23:JCO2400529. doi: 10.1200/JCO.24.00529. Online ahead of print. J Clin Oncol. 2024. PMID: 39442070
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.
Neven P, Fasching PA, Chia S, Jerusalem G, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Zarate JP, Wang Y, Chakravartty A, Wang C, Slamon DJ. Neven P, et al. Among authors: bianchi gv. Breast Cancer Res. 2023 Aug 31;25(1):103. doi: 10.1186/s13058-023-01701-9. Breast Cancer Res. 2023. PMID: 37653397 Free PMC article. Clinical Trial.
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial.
Malorni L, Bianchini G, Caputo R, Zambelli A, Puglisi F, Bianchi GV, Del Mastro L, Paris I, Montemurro F, Allegrini G, Colleoni M, Tamberi S, Zamagni C, Cazzaniga ME, Orditura M, Guarneri V, Castelletti D, Benelli M, Di Marino M, Arpino G, De Laurentiis M. Malorni L, et al. Among authors: bianchi gv. Eur J Cancer. 2023 Jun;186:1-11. doi: 10.1016/j.ejca.2023.03.001. Epub 2023 Mar 8. Eur J Cancer. 2023. PMID: 37003098 Free article. Clinical Trial.
Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison.
Lobefaro R, Mariani L, Peverelli G, Ligorio F, Fucà G, Rametta A, Zattarin E, Leporati R, Presti D, Cantarelli B, Depretto C, Vingiani A, Manoukian S, Scaperrotta G, Bianchi GV, Capri G, Pruneri G, de Braud F, Vernieri C. Lobefaro R, et al. Among authors: bianchi gv. Clin Breast Cancer. 2023 Apr;23(3):e151-e162. doi: 10.1016/j.clbc.2022.12.008. Epub 2022 Dec 17. Clin Breast Cancer. 2023. PMID: 36599769 Free article.
Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin.
Zattarin E, Nichetti F, Ligorio F, Mazzeo L, Lobefaro R, Fucà G, Peverelli G, Vingiani A, Bianchi GV, Capri G, de Braud F, Vernieri C. Zattarin E, et al. Among authors: bianchi gv. Front Oncol. 2022 Aug 18;12:925551. doi: 10.3389/fonc.2022.925551. eCollection 2022. Front Oncol. 2022. PMID: 36059635 Free PMC article.
Early stage breast cancer follow-up in real-world clinical practice: the added value of cell free circulating tumor DNA.
La Rocca E, De Santis MC, Silvestri M, Ortolan E, Valenti M, Folli S, de Braud FG, Bianchi GV, Scaperrotta GP, Apolone G, Daidone MG, Cappelletti V, Pruneri G, Di Cosimo S. La Rocca E, et al. Among authors: bianchi gv. J Cancer Res Clin Oncol. 2022 Jun;148(6):1543-1550. doi: 10.1007/s00432-022-03990-7. Epub 2022 Apr 9. J Cancer Res Clin Oncol. 2022. PMID: 35396978 Free PMC article.
48 results